Skip to main content

Table 1 MED12 mutations, HMGA2 aberrations, and biallelic FH inactivation in uterine smooth muscle tumors

From: Characterization of MED12, HMGA2, and FH alterations reveals molecular variability in uterine smooth muscle tumors

Smooth muscle tumor subtype Total MED12 mutation positive HMGA2 overexpressing FH deficient
N % P-value 95% CI N % P-value 95% CI N % P-value 95% CI
Conventional 65 37 56.9    16 24.6    0 0   
Histopathological UL variant 94 17 18.1 5.2 × 10−7 2.76–13.14 13 13.8 0.10 0.83–5.01 8 8.5 0.02 0.00–0.81
 Mitotically active 25 9 36 0.10 0.83–6.93 1 4 0.03 1.07–341.56 0 0   
 Leiomyoma with bizarre nuclei 18 3 16.7 3.0 × 10−3 1.61–38.18 0 0 0.02 1.24- ∞ 6 33.3 4.9 × 10−5 0.00–0.19
 Cellular 25 4 16 7.3 × 10−4 1.98–30.31 8 32 0.60 0.23–2.23 1 4 0.28 0.00–15.00
 Highly cellular 37 3 8.1 6.0 × 10−7 3.98–81.73 4 10.8 0.12 0.77–11.96 1 2.7 0.36 0.00–22.20
Leiomyosarcoma 51 11 21.6 1.4 × 10−4 1.96–12.16 3 5.9 0.01 1.35–29.40 2 3.9 0.19 0.00–4.16
  1. Eleven mitotically active leiomyomas with increased cellularity were included in both mitotically active and cellular/highly cellular leiomyoma subtypes for statistical testing